Blueprint Medicines Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Blueprint Medicines (BPMC) Tops Q1 EPS by 6c, Revenues Beat
May 6, 2020 7:19 AM EDTBlueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($2.11), $0.06 better than the analyst estimate of ($2.17). Revenue for the quarter came in at $6.16 million versus the consensus estimate of $5.44 million.
"Our progress in recent months is a testament to the agility of the Blueprint... More
